DexComXSWX:DXCM 90 Forward PE Ratio is 27.98 as of Jun. 26, 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 393 Medical Devices & Instruments companies, DexCom ranks worse than 70.23% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
DexCom Forward PE Ratio Related Terms
DexCom Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for DexCom's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom Forward PE Ratio Chart
DexCom Annual Data
Trend
Forward PE Ratio
DexCom Quarterly Data
2026-03
Forward PE Ratio
27.49
XSWX:DXCM vs GEHC, STE, ZBH: Forward PE Ratio Comparison
For the Medical Devices subindustry, DexCom's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where DexCom's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
DexCom (XSWX:DXCM) has a Forward PE Ratio of 27.98 as of Jun. 26, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on DexCom and its competitors. According to the industry distribution chart, DexCom ranks #276 out of 393 companies in the Medical Devices & Instruments industry, placing it in the top 70.2%.
Is DexCom's Forward PE Ratio too high?
DexCom's current Forward PE Ratio is 27.98. The Medical Devices & Instruments industry median Forward PE Ratio is 18.62. DexCom's value of 27.98 is 50.3% above this industry median. Based on the distribution chart, DexCom ranks #276 out of 393 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Forward PE Ratio compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #276 out of 393 companies for Forward PE Ratio. This places DexCom in the lower half of its industry. The industry median Forward PE Ratio is 18.62. DexCom's value of 27.98 is 50.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 18.62, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current Forward PE Ratio of 27.98 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 18.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current Forward PE Ratio is 27.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Forward PE Ratio of 27.98. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Forward PE Ratio is 27.98 and 50.3% above the Medical Devices & Instruments industry median of 18.62. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Forward PE Ratio is 27.98 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (XSWX:DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.
Key valuation signals for XSWX:DXCM:
Forward PE Ratio: 27.98
GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
Industry Position: 50.3% above the Medical Devices & Instruments median (#276 of 393)
No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for XSWX:DXCM
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DXCM has been successfully added to your 